These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29512068)

  • 1. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma.
    Vogelgsang J; Wiltfang J; Klafki HW
    Methods Mol Biol; 2018; 1750():111-124. PubMed ID: 29512068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V; Fandos N; Canudas J; Insua D; Casabona D; Lacosta AM; Montañés M; Pesini P; Sarasa M
    J Alzheimers Dis; 2016 Sep; 54(2):751-62. PubMed ID: 27567833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.
    Klafki HW; Hafermann H; Bauer C; Haussmann U; Kraus I; Schuchhardt J; Muck S; Scherbaum N; Wiltfang J
    J Alzheimers Dis; 2016 Sep; 54(2):691-705. PubMed ID: 27567847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Technical Validation of an Immunoassay for the Detection of APP
    Klafki HW; Rieper P; Matzen A; Zampar S; Wirths O; Vogelgsang J; Osterloh D; Rohdenburg L; Oberstein TJ; Jahn O; Beyer I; Lachmann I; Knölker HJ; Wiltfang J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of plasma β-amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer's disease.
    Wang D; Dai Y; Wang X; Yu P; Qu S; Liu Z; Cao Y; Zhang L; Ping Y; Liu W; Tao Z
    Mikrochim Acta; 2021 Jan; 188(1):24. PubMed ID: 33404755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.
    Mehta PD; Patrick BA; Miller DL; Coyle PK; Wisniewski T
    J Alzheimers Dis; 2020; 78(3):1237-1244. PubMed ID: 33252086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.
    Bittner T; Zetterberg H; Teunissen CE; Ostlund RE; Militello M; Andreasson U; Hubeek I; Gibson D; Chu DC; Eichenlaub U; Heiss P; Kobold U; Leinenbach A; Madin K; Manuilova E; Rabe C; Blennow K
    Alzheimers Dement; 2016 May; 12(5):517-26. PubMed ID: 26555316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1-40) and (1-42) in plasma samples.
    Yamashita K; Watanabe S; Ishiki K; Miura M; Irino Y; Kubo T; Matsui J; Hagino K; Iwanaga S; Yoshida T
    Biochem Biophys Res Commun; 2021 Oct; 576():22-26. PubMed ID: 34478915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.
    Song L; Lachno DR; Hanlon D; Shepro A; Jeromin A; Gemani D; Talbot JA; Racke MM; Dage JL; Dean RA
    Alzheimers Res Ther; 2016 Dec; 8(1):58. PubMed ID: 27978855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.
    Lachno DR; Emerson JK; Vanderstichele H; Gonzales C; Martényi F; Konrad RJ; Talbot JA; Lowe SL; Oefinger PE; Dean RA
    J Alzheimers Dis; 2012; 32(4):905-18. PubMed ID: 22886018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma amyloid beta peptides: an Alzheimer's conundrum or a more accessible Alzheimer's biomarker?
    Poljak A; Sachdev PS
    Expert Rev Neurother; 2017 Jan; 17(1):3-5. PubMed ID: 27454742
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.
    Llorens F; Kruse N; Schmitz M; Shafiq M; da Cunha JE; Gotzman N; Zafar S; Thune K; de Oliveira JR; Mollenhauer B; Zerr I
    J Neurol; 2015 Oct; 262(10):2305-11. PubMed ID: 26162713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease.
    Iwatsubo T
    Neurobiol Aging; 1998; 19(2):161-3. PubMed ID: 9558155
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.
    Bogstedt A; Groves M; Tan K; Narwal R; McFarlane M; Höglund K
    J Alzheimers Dis; 2015; 46(4):1091-101. PubMed ID: 26402635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
    J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma.
    Oh ES; Mielke MM; Rosenberg PB; Jain A; Fedarko NS; Lyketsos CG; Mehta PD
    J Alzheimers Dis; 2010; 21(3):769-73. PubMed ID: 20634583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.
    Le Bastard N; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2010; 21(1):291-301. PubMed ID: 20421698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with Flow cytometry and its application in the diagnostics of Alzheimer's disease.
    Santos AN; Simm A; Holthoff V; Boehm G
    J Alzheimers Dis; 2008 Jun; 14(2):127-31. PubMed ID: 18560125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer disease: Biomarkers of AD risk - the end of the road for plasma amyloid-β?
    Wood H
    Nat Rev Neurol; 2016 Nov; 12(11):613. PubMed ID: 27739538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.